First human test of experimental cancer drug shows early safety profile
NCT ID NCT06894771
Summary
This early-stage study tested the safety of a new cancer drug called MK-4700, both alone and combined with an existing immunotherapy (pembrolizumab). It involved just 5 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find safe dosage levels and understand how the drug behaves in the body, not to prove it works against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102)
Québec, Quebec, G1J 1Z4, Canada
-
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301)
Hackensack, New Jersey, 07601, United States
-
NEXT Oncology ( Site 0300)
San Antonio, Texas, 78229, United States
-
Princess Margaret Cancer Center ( Site 0101)
Toronto, Ontario, M5G 2M9, Canada
-
Rabin Medical Center ( Site 0202)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus ( Site 0201)
Haifa, 3109601, Israel
-
Sheba Medical Center ( Site 0200)
Ramat Gan, 5265601, Israel
Conditions
Explore the condition pages connected to this study.